Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Allopregnanolone
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Relmada Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Relmada Acquires Tourette Therapy from Asarina Pharma
Details : Relmada acquires Isoallopregnanolone (sepranolone) from Asarina. Sepranolone is a first-in-class GABAA Modulating Steroid Antagonist (GAMSA), being evaluated for Tourette syndrome.
Product Name : Isoallopregnanolone
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 06, 2025
Lead Product(s) : Allopregnanolone
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Relmada Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Allopregnanolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Asarina Pharma Reports Topline Results from Phase Iib Study in PMDD
Details : Substantial reduction in PMDD symptoms was achieved across the patient population, but, in comparison to placebo, primary and secondary endpoints were not statistically significant.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : Allopregnanolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable